Mereo BioPharma Group plc (NASDAQ:MREO – Get Free Report) General Counsel Charles Sermon sold 9,980 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $4.47, for a total transaction of $44,610.60. Following the completion of the sale, the general counsel now owns 240,007 shares in the company, valued at $1,072,831.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Charles Sermon also recently made the following trade(s):
- On Tuesday, June 25th, Charles Sermon sold 14,202 shares of Mereo BioPharma Group stock. The shares were sold at an average price of $3.69, for a total transaction of $52,405.38.
Mereo BioPharma Group Stock Performance
NASDAQ MREO opened at $3.95 on Wednesday. Mereo BioPharma Group plc has a 52 week low of $3.64 and a 52 week high of $5.02. The stock’s 50 day moving average price is $4.21 and its two-hundred day moving average price is $3.61.
Analyst Ratings Changes
View Our Latest Stock Report on Mereo BioPharma Group
Institutional Trading of Mereo BioPharma Group
A number of institutional investors have recently made changes to their positions in the business. Rhumbline Advisers increased its stake in Mereo BioPharma Group by 70.9% in the 2nd quarter. Rhumbline Advisers now owns 6,958 shares of the company’s stock valued at $25,000 after buying an additional 2,887 shares during the last quarter. Advisors Preferred LLC bought a new position in shares of Mereo BioPharma Group in the 1st quarter valued at about $28,000. SG Americas Securities LLC acquired a new stake in shares of Mereo BioPharma Group in the first quarter valued at about $54,000. BNP Paribas Financial Markets raised its holdings in Mereo BioPharma Group by 581,066.7% during the first quarter. BNP Paribas Financial Markets now owns 17,435 shares of the company’s stock worth $58,000 after acquiring an additional 17,432 shares in the last quarter. Finally, Index Fund Advisors Inc. acquired a new position in Mereo BioPharma Group during the first quarter valued at approximately $99,000. Institutional investors own 62.83% of the company’s stock.
Mereo BioPharma Group Company Profile
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
Further Reading
- Five stocks we like better than Mereo BioPharma Group
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- P/E Ratio Calculation: How to Assess Stocks
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.